AI-ACCELERATED DRUG DISCOVERY

Very-long-chain 3-oxoacyl-CoA reductase

Explore its Potential with AI-Driven Innovation
Predicted by Alphafold

Very-long-chain 3-oxoacyl-CoA reductase - Focused Library Design

Available from Reaxense

This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Very-long-chain 3-oxoacyl-CoA reductase including:

1. LLM-powered literature research

Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Very-long-chain 3-oxoacyl-CoA reductase therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.

 Fig. 1. Preliminary target research workflow

2. AI-Driven Conformational Ensemble Generation

Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Very-long-chain 3-oxoacyl-CoA reductase, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.

 Fig. 2. AI-powered molecular dynamics simulations workflow

3. Binding pockets identification and characterization

We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.

 Fig. 3. AI-based binding pocket detection workflow

4. AI-Powered Virtual Screening

Our ecosystem is equipped to perform AI-driven virtual screening on Very-long-chain 3-oxoacyl-CoA reductase. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Very-long-chain 3-oxoacyl-CoA reductase. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.

 Fig. 4. The screening workflow of Receptor.AI

Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.

The focused library for Very-long-chain 3-oxoacyl-CoA reductase includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Very-long-chain 3-oxoacyl-CoA reductase

partner:

Reaxense

upacc:

Q53GQ0

UPID:

DHB12_HUMAN

Alternative names:

17-beta-hydroxysteroid dehydrogenase 12; 3-ketoacyl-CoA reductase; Estradiol 17-beta-dehydrogenase 12; Short chain dehydrogenase/reductase family 12C member 1

Alternative UPACC:

Q53GQ0; A8K9B0; D3DR23; Q96EA9; Q96JU2; Q9Y6G8

Background:

Very-long-chain 3-oxoacyl-CoA reductase, known alternatively as 17-beta-hydroxysteroid dehydrogenase 12, plays a crucial role in the elongation of long-chain fatty acids. This enzyme operates within the endoplasmic reticulum, catalyzing the reduction of 3-ketoacyl-CoA to 3-hydroxyacyl-CoA, a key step in the production of very long-chain fatty acids (VLCFAs). VLCFAs serve as precursors for membrane lipids and lipid mediators, essential for cellular function and signaling.

Therapeutic significance:

Understanding the role of Very-long-chain 3-oxoacyl-CoA reductase could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.